iTeos Therapeutics (NASDAQ:ITOS) Receives “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report report published on Friday morning,RTT News reports. They currently have a $25.00 target price on the stock.

Several other equities research analysts have also recently weighed in on ITOS. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research note on Friday, December 13th. Wells Fargo & Company reduced their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th.

iTeos Therapeutics Stock Performance

ITOS opened at $7.76 on Friday. iTeos Therapeutics has a 52-week low of $7.09 and a 52-week high of $18.75. The stock has a market capitalization of $283.50 million, a PE ratio of -2.46 and a beta of 1.39. The stock’s 50 day moving average price is $8.13 and its 200-day moving average price is $11.78.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.13. Research analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares of the company’s stock, valued at $505,766.17. The trade was a 8.27 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC lifted its holdings in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of iTeos Therapeutics during the third quarter valued at $31,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares in the last quarter. Virtu Financial LLC bought a new position in shares of iTeos Therapeutics during the third quarter valued at $102,000. Finally, Quest Partners LLC lifted its holdings in shares of iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after purchasing an additional 9,934 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.